-
FDA approves Vyxeos for acute myeloid leukemia
SILVER SPRING, Md. — A new treatment for certain types of acute myeloid leukemia has been cleared by the Food and Drug Administration. Jazz Pharmaceuticals’ Vyxeos was approved for newly diagnosed therapy-related AML or AML with myelodysplasia-related changesFDA approves Imbruvica expansion to treat chronic graft versus host disease
SILVER SPRING, Md. — Janssen Biotech and Pharmacyclics’ Imbruvica (ibrutinib) has a new indication. The Food and Drug Administration on Wednesday approved the drug to treat adults with chronic graft versus host disease after one or more treatments have failed.
This approval makes Imbruvica the first FDA-approved treatment for the illness, which afflicts patients who have received hematopoietic stem cell transplantation to treat blood or bone marrow cancers. The illness occurs when cells from the stem cell transplant attack healthy cells in a patient’s tissues.
XThis ad will auto-close in 10 seconds